The changing landscape of phase II/III metastatic NSCLC clinical trials and the importance of biomarker selection criteria

Publisher： Blackwell Publishing

E-ISSN： 1097-0142|120|24|3853-3858

ISSN： 0008-543X

Source： Cancer, Vol.120, Iss.24, 2014-12, pp. : 3853-3858

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Group-Sequential Methods for Adaptive Seamless Phase II/III Clinical Trials

By Stallard Nigel  

Journal of Biopharmaceutical Statistics, Vol. 21, Iss. 4, 2011-07 ,pp. : 787-801

Taylor & Francis Ltd

Access to resources Recommend Favorite

Cancer Vaccines in Phase II/III Clinical Trials: State of the Art and Future Perspectives

By  

Current Cancer Drug Targets, Vol. 11, Iss. 1, 2011-01 ,pp. : 85-102

Bentham Science Publishers

Access to resources Recommend Favorite

An Adaptive Design for Phase II Non-Oncology Dose Selection Clinical Trials

By Su Zheng  

Clinical Drug Investigation, Vol. 30, Iss. 6, 2010-06 ,pp. : 397-403

Adis International

Access to resources Recommend Favorite

Randomized Phase II Clinical Trials

By    

Journal of Biopharmaceutical Statistics, Vol. 24, Iss. 4, 2014-07 ,pp. : 802-816

Taylor & Francis Ltd

Access to resources Recommend Favorite

SarCNU in recurrent or metastatic colorectal cancer: A phase II study of the National Cancer Institute of Canada Clinical Trials Group

By Wong R.   Baetz T.   Krahn M.   Biagi J.   Wainman N.   Eisenhauer E.  

Investigational New Drugs, Vol. 24, Iss. 4, 2006-07 ,pp. : 347-351

Springer Publishing Company

Access to resources Recommend Favorite